Company on track to deliver five Investigational New Drug (IND) applications as part of ‘5 by 5’ solid tumor strategy 18 ...

The principle of immune checkpoint blockade therapy is based on the activation of T cells. Immune checkpoint inhibitors (ICIs), such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, have demonstrated ...

The immune system is endowed with the capacity to distinguish between self and non-self, so-called immune tolerance or “consciousness of the immune system.” This type of awareness is designed to ...

Nanomedicine. 2013;8(7):1173-1189. To date, nearly all acellular aAPC systems have utilized spherical particles in their constructs. However, both the dramatic morphological changes that come with ...

AP Biosciences is committed to transforming cancer treatment through the development of cutting-edge bispecific antibodies. Enabled by the company’s proprietary Omni-Mab Discovery Library and T-CUBE T ...

Monoclonal antibodies in the therapy of rheumatic diseases The turn of the century brought the beginning of the era of monoclonal antibody therapy in rheumatology. Advances in technology have led ...

One of the advantages of a biodegradable aAPC system compared with a nondegradable aAPC system is that the biodegradable system can be engineered to release soluble factors from within the aAPC in ...

The role of PD-1 blockade in the adjuvant setting was examined in the EORTC 1325/KEYNOTE-054 trial (55). In patients with completely resected stage III melanoma, pembrolizumab, an anti-PD-1 monoclonal ...